Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Lifeworks Advisors LLC

Lifeworks Advisors LLC trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 77,119 shares of the biopharmaceutical company’s stock after selling 275 shares during the period. Gilead Sciences makes up about 1.3% of Lifeworks Advisors LLC’s holdings, making the stock its 17th largest holding. Lifeworks Advisors LLC’s holdings in Gilead Sciences were worth $6,466,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Koshinski Asset Management Inc. purchased a new stake in Gilead Sciences during the first quarter worth about $217,000. TD Asset Management Inc lifted its holdings in Gilead Sciences by 2.5% during the 1st quarter. TD Asset Management Inc now owns 1,055,180 shares of the biopharmaceutical company’s stock worth $77,292,000 after buying an additional 25,523 shares in the last quarter. Trillium Asset Management LLC boosted its position in Gilead Sciences by 25.0% in the 1st quarter. Trillium Asset Management LLC now owns 164,129 shares of the biopharmaceutical company’s stock valued at $12,022,000 after buying an additional 32,792 shares during the period. Dorsey & Whitney Trust CO LLC grew its stake in shares of Gilead Sciences by 16.1% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 12,613 shares of the biopharmaceutical company’s stock worth $924,000 after acquiring an additional 1,746 shares in the last quarter. Finally, GM Advisory Group LLC purchased a new stake in shares of Gilead Sciences during the first quarter worth $263,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

NASDAQ GILD traded down $0.76 during trading on Thursday, reaching $91.87. The company’s stock had a trading volume of 1,267,529 shares, compared to its average volume of 7,050,061. The business’s fifty day moving average price is $86.22 and its 200-day moving average price is $75.69. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.82 and a current ratio of 1.11. The firm has a market cap of $114.38 billion, a price-to-earnings ratio of 1,029.22, a P/E/G ratio of 2.91 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the previous year, the firm posted $2.29 EPS. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. As a group, analysts anticipate that Gilead Sciences, Inc. will post 4.39 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Analyst Upgrades and Downgrades

GILD has been the subject of several analyst reports. Sanford C. Bernstein started coverage on Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their target price for the company from $74.00 to $96.00 in a report on Monday, October 21st. Royal Bank of Canada boosted their price target on shares of Gilead Sciences from $75.00 to $81.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Finally, Robert W. Baird raised their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.10.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,947 shares of company stock valued at $4,968,674. 0.16% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.